Allan Ben Smith1,2, Phyllis Butow3, Ian Olver4, Tim Luckett5, Peter Grimison6,7, Guy C Toner6,8, Martin R Stockler6,9,10, Elizabeth Hovey6,11, John Stubbs6,12, Sandra Turner13, George Hruby9,10, Howard Gurney13, Mahmood Alam14, Keith Cox9, Madeleine T King3,6,15. 1. Psycho-Oncology Co-operative Research Group (PoCoG), Chris O'Brien Lifehouse (C39Z), University of Sydney, Sydney, NSW, 2006, Australia. allan.smith@sydney.edu.au. 2. Australian and New Zealand Urogenital and Prostate Cancer Trials Group Limited (ANZUP), Sydney, NSW, Australia. allan.smith@sydney.edu.au. 3. Psycho-Oncology Co-operative Research Group (PoCoG), Chris O'Brien Lifehouse (C39Z), University of Sydney, Sydney, NSW, 2006, Australia. 4. Sansom Institute for Health Research, University of South Australia, Adelaide, SA, Australia. 5. Improving Palliative Care through Clinical Trials (ImPaCCT), South Western Sydney Clinical School, The University of New South Wales, and Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia. 6. Australian and New Zealand Urogenital and Prostate Cancer Trials Group Limited (ANZUP), Sydney, NSW, Australia. 7. Chris O'Brien Lifehouse and University of Sydney, Sydney, NSW, Australia. 8. Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia. 9. Chris O'Brien Lifehouse, Sydney, NSW, Australia. 10. Concord Cancer Centre, Concord Repatriation General Hospital, Sydney, NSW, Australia. 11. Prince of Wales Hospital, Sydney, NSW, Australia. 12. CanSpeak, Sydney, NSW, Australia. 13. Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia. 14. Liverpool Hospital, Sydney, NSW, Australia. 15. Central Clinical School, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Abstract
PURPOSE: This study aimed to establish the prevalence, severity, and correlates of psychological distress and impaired generic health-related quality of life (HRQOL) in testicular cancer (TC) survivors. METHODS: Men who had completed active anti-cancer treatment for TC between 6 months and 5 years previously showing no evidence of recurrence were recruited from 14 Australian cancer centers from September 2009 to February 2011. Participants completed a self-report questionnaire measuring demographic, disease, and treatment information, psychological distress (i.e., depression, anxiety, and stress; DASS21), generic health-related quality of life (HRQOL; SF-36v2), TC-specific HRQOL (EORTC QLQ-TC26), coping (MAC), social support (DUFSS), and unmet needs (CaSUN). RESULTS: Of 486 eligible TC survivors, 244 (50.2%) completed the questionnaire. Compared with normative data, TC survivors reported: small but statistically significant increases in mean levels of anxiety and depression; a greater prevalence of moderate to extremely severe anxiety (19%) and depression (20%); and significant deficits to mostly mental aspects of generic HRQOL. The most problematic TC-specific HRQOL issues (e.g., fear of recurrence) were also more mental than physical. In multiple regression analyses, the strongest correlates of psychological distress and impaired generic HRQOL were psychosocial (e.g., helpless/hopeless coping and lower social support) rather than disease or treatment factors. CONCLUSIONS: Generally, TC survivors appear to experience mild psychological distress and HRQOL impairments, while a vulnerable subgroup experience more severe morbidity. IMPLICATIONS FOR CANCER SURVIVORS: There is a need to identify TC survivors at risk of poorer outcomes and for interventions to target the areas of greatest impairment (i.e., psychological distress and mental HRQOL).
PURPOSE: This study aimed to establish the prevalence, severity, and correlates of psychological distress and impaired generic health-related quality of life (HRQOL) in testicular cancer (TC) survivors. METHODS:Men who had completed active anti-cancer treatment for TC between 6 months and 5 years previously showing no evidence of recurrence were recruited from 14 Australian cancer centers from September 2009 to February 2011. Participants completed a self-report questionnaire measuring demographic, disease, and treatment information, psychological distress (i.e., depression, anxiety, and stress; DASS21), generic health-related quality of life (HRQOL; SF-36v2), TC-specific HRQOL (EORTC QLQ-TC26), coping (MAC), social support (DUFSS), and unmet needs (CaSUN). RESULTS: Of 486 eligible TC survivors, 244 (50.2%) completed the questionnaire. Compared with normative data, TC survivors reported: small but statistically significant increases in mean levels of anxiety and depression; a greater prevalence of moderate to extremely severe anxiety (19%) and depression (20%); and significant deficits to mostly mental aspects of generic HRQOL. The most problematic TC-specific HRQOL issues (e.g., fear of recurrence) were also more mental than physical. In multiple regression analyses, the strongest correlates of psychological distress and impaired generic HRQOL were psychosocial (e.g., helpless/hopeless coping and lower social support) rather than disease or treatment factors. CONCLUSIONS: Generally, TC survivors appear to experience mild psychological distress and HRQOL impairments, while a vulnerable subgroup experience more severe morbidity. IMPLICATIONS FOR CANCER SURVIVORS: There is a need to identify TC survivors at risk of poorer outcomes and for interventions to target the areas of greatest impairment (i.e., psychological distress and mental HRQOL).
Entities:
Keywords:
Health-related quality of life; Oncology; Psychological distress; Survivorship; Testicular cancer
Authors: Anette Fischer Pedersen; Philip Rossen; Frede Olesen; Hans von der Maase; Peter Vedsted Journal: Psychooncology Date: 2011-08-25 Impact factor: 3.894
Authors: Johanna Skoogh; Gunnar Steineck; Ulrika Stierner; Eva Cavallin-Ståhl; Ulrica Wilderäng; Anders Wallin; Margaret Gatz; Boo Johansson Journal: Acta Oncol Date: 2011-08-18 Impact factor: 4.089
Authors: Hege S Haugnes; George J Bosl; Hink Boer; Jourik A Gietema; Marianne Brydøy; Jan Oldenburg; Alv A Dahl; Roy M Bremnes; Sophie D Fosså Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544
Authors: Noa Shani Shrem; Lori Wood; Robert J Hamilton; Kopika Kuhathaas; Piotr Czaykowski; Matthew Roberts; Andrew Matthew; Jason P Izard; Peter Chung; Lucia Nappi; Jennifer Jones; Denis Soulières; Armen Aprikian; Nicholas Power; Christina Canil Journal: Can Urol Assoc J Date: 2022-08 Impact factor: 2.052